The EAP launch is a modest positive for patient access optics but does not derisk APOLLO. Key binary catalyst is APOLLO topline data in Q4 2026; the mid-2027 FDA decision timeline reinforces that near-term stock movement will be driven by Phase 3 results, not today's announcement. Traders should focus on APOLLO enrollment and data timing updates.
Price Chart
Executive Summary
Disc Medicine launched an expanded access program (EAP) for bitopertin in erythropoietic protoporphyria (EPP)/X-linked protoporphyria (XLP) patients in the U.S., while noting that Phase 3 APOLLO topline data is expected in Q4 2026, with a CRL response and FDA decision expected by mid-2027. This is a procedural step that does not change the binary risk/reward of the upcoming Phase 3 readout and regulatory decision, and does not add new safety/efficacy data.
Key Facts
- EAP launched for bitopertin in eligible EPP/XLP patients aged 12+ in the U.S.
- Phase 3 APOLLO double-blind, placebo-controlled trial ongoing; topline data expected Q4 2026
- Disc Medicine expects to submit a CRL response with FDA decision by mid-2027
- Bitopertin is not approved in any jurisdiction; an earlier CRL prompted the updated timeline
- Company market cap ~$2.7B; analyst consensus is heavily bullish (95% buy-side)
Financial Impact
No financial data provided in this press release; the EAP is a non-revenue-generating program
Risk Factors
- Phase 3 APOLLO may fail to meet primary endpoint, as bitopertin previously received a CRL
- CRL response may be rejected by FDA, delaying or preventing approval beyond mid-2027
- EAP access does not guarantee favorable regulatory outcome or commercial adoption
- High cash burn for clinical-stage biotech with no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304352 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 9, 2026 22d ago | Press Release | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 3, 2026 28d ago | Insider Cluster | $79.23 $68.92 | ▲ +13.01% | ▲ +11.80% | $64.48 (+18.62%) |
Sep 2, 2026 29d ago | 144 | $79.37 $70.06 | ▼ −11.73% | ▼ −10.58% | $64.48 (−18.76%) |
Aug 27, 2026 5w ago | Insider Cluster | $82.55 $79.37 | ▼ −3.85% | ▼ −4.12% | $64.48 (−21.89%) |
Aug 18, 2026 6w ago | Insider Cluster | $80.32 $82.67 | ▲ +2.93% | ▲ +3.31% | $64.48 (−19.72%) |
Aug 14, 2026 6w ago | Insider Cluster | $80.05 $80.94 | ▲ +1.11% | ▲ +2.30% | $64.48 (−19.45%) |
Jul 30, 2026 9w ago | 8-K | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 30, 2026 9w ago | Press Release | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 14, 2026 11w ago | Insider Cluster | $76.02 $74.32 | ▼ −2.24% | ▼ −1.26% | $64.48 (−15.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access